


California

Bristol Myers Squibb's robust presence in California is transforming the way cancer and other difficult-to-treat diseases are approached. Scientists and researchers with diverse backgrounds and expertise in the **San Francisco Bay Area** and **San Diego** collaborate across teams, functions and sites to follow their own scientific curiosity, enabling fast, flexible science that may ultimately increase the efficiency and success of drugs in the clinic.

Our single vision is to transform patients' lives through science and guide our teams as we deliver our medicines to people living with serious illnesses.



Areas of Focus

Brisbane is home to research teams in **early and clinical development** across all therapeutic research areas including hematology, oncology and cardiovascular disease. Our Early Clinical Development (ECD-HOCT) team leads early clinical development programs for both internal and partnered assets for a diverse range of hematology, oncology and cell therapy pipeline assets such as CAR T cells, T-cell engagers, monoclonal antibodies, protein degraders, small molecules and traditional and complex biologics.

Redwood City is the home of our Tumor Microenvironment thematic research center (TME TRC), where we collaborate closely with discovery and translational scientists to research how we can **harness the body's immune system to better target tumors**. The TME TRC teams are focused on developing therapeutics at the intersection of stromal, tumor and immune biology with the goal of enhancing responsiveness to therapies and improving response and durability rates for patients with cancer.

San Diego's concentration is on the exploration of **novel biology, target concepts and complex biologics**, aiming to better understand and modulate the processes that lead to cancer, autoimmune and neurodegenerative diseases with significant unmet need. Protein degradation is a core strength for Bristol Myers Squibb R&D, and we are building on our legacy and scientific expertise to discover and develop therapeutic approaches in blood cancers, solid tumors and other important therapeutic areas.

San Francisco's team of translational scientists work at the intersection of discovery and clinical drug development to pursue findings in **protein degradation**. This team collaborates with several of our broader thematic research centers in predictive sciences and biosample operations across the country.

Scientific and Corporate Investments



Jobs

Bristol Myers Squibb provides high-quality jobs for residents across the state and currently employs approximately 863 employees* in California, with a total payroll of \$473.4 million.

*As of June 2021



Investments

In 2021, economic investment in a wide range of local businesses through vendor relationships totaled \$973 million in California.



Clinical Trials

Bristol Myers Squibb conducted activities to support 157 clinical trials at 439 clinical trial study sites in 2021.

Making a Difference at Work and in the Community

Our commitment to California means working to support and strengthen the communities in which we work and live.



Local Community Support

We support programs, initiatives and organizations such as Calculus Roundtable, the Jacobs & Cushman San Diego Food Bank, Kits Cubed, Pursuit of Excellence, San Diego Festival of Science and Engineering and Second Harvest that help improve health, promote STEM education and deliver basic human services to our communities.



Corporate & Community Giving


In 2021, we delivered more than \$6.2 million in giving and sponsorship support to a range of local organizations and programs serving communities in California.



Focus on Patients

Bristol Myers Squibb supports the Bristol Myers Squibb Foundation, an independent nonprofit whose mission is to promote health equity and to improve the health outcomes of populations disproportionately affected by serious diseases.

More than 250 grants were awarded totaling \$31.3 million across the U.S. in 2021.



Global Inclusion and Diversity

In 2020, Bristol Myers Squibb and the Bristol Myers Squibb Foundation each separately committed \$150 million over five years to help address health disparities, increase clinical trial diversity, expand supplier diversity, enhance employee giving and increase executive diversity in our workforce. We believe that these commitments will help improve outcomes and transform the lives of patients and communities in the United States and globally.



Supplier Diversity

In 2021, Bristol Myers Squibb spent \$105 million with diverse suppliers in California. Bristol Myers Squibb's Supplier Diversity Program is centered around an ethos of Partnering with Purpose. The organization exists to champion economic empowerment, wealth creation and job creation in the community, while fostering inclusive innovation and a supply chain that reflects the company's values, its patients and the world.



Protecting the Environment

As we experienced significant business growth, our company also has been able to reduce operation-generated greenhouse gas emissions by more than 20% and water use by more than 10% over our 2015 baselines.



Product Donation

Bristol Myers Squibb helps patients through product donations to independent charitable organizations, including the Bristol Myers Squibb Patient Assistance Foundation, an independent nonprofit that assists financially needy patients who are uninsured or underinsured.

It provided a \$1.75 billion value of free medicine to 138,360 patients in the U.S. in 2021.